Actelion announces changes to its executive team upon completion of the transaction with Johnson
& Johnson


Actelion Pharmaceuticals Ltd /
Actelion announces changes to its executive team upon completion of the 
transaction with Johnson & Johnson 
. Verarbeitet und übermittelt durch Nasdaq Corporate Solutions.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Source: Globenewswire

ALLSCHWIL/BASEL,  SWITZERLAND  -  15 May  2017 - Actelion  Ltd (SIX: ATLN) today
announced changes to its executive team that would only take effect upon closing
of the transaction with Johnson & Johnson expected towards the end of the second
quarter 2017.

Johnson  & Johnson has appointed Jane Griffiths  as the Global Head of Actelion,
to take effect upon closing of the transaction.

Dr. Griffiths, PhD has served as the Company Group Chairman, Janssen EMEA, since
January  2011. Prior to leading  Janssen EMEA, she  was responsible for the EMEA
Market  Access unit.  She has  also served  as International  Vice President for
Janssen-Cilag  Northern  Europe;  Vice  President,  EMEA Biopharmaceuticals; and
Managing Director, Ortho Biotech UK & Ireland.

Otto  Schwarz, PhD,  will retire  from his  position as Chief Operating Officer,
upon  close of  the transaction.  He will  work closely  with Jane  Griffiths as
senior  advisor for the 12 months following the completion of the transaction on
the  smooth  integration  of  Actelion  into  Janssen/Johnson & Johnson  and the
seamless  execution of Actelion's  commercial strategies to  maintain the strong
momentum.

Jean-Paul Clozel, MD, Chief Executive Officer, commented: "I would like to thank
Otto  for his very significant  contributions to the success  of Actelion in the
almost  9 years since he  joined the company.  Under his leadership Tracleer was
built into a global brand with almost 1.7 billion Swiss francs in peak sales. He
also  led and  managed the  highly successful  launches of  Opsumit, Uptravi and
Veletri,  thus replacing  the leading  drug in  the category with a diversified,
outcome-based  portfolio,  which  has  a  strong  long-term  growth potential to
achieve  leading  positions  in  shaping  the  treatment  paradigms  in  PAH, an
achievement which is a rare feat  in our industry."

                                      ###

 NOTES TO EDITORS

Actelion Ltd.

Actelion  Ltd. is a leading biopharmaceutical  company focused on the discovery,
development   and  commercialization  of  innovative  drugs  for  diseases  with
significant unmet medical needs.

Actelion  is a leader in the field of pulmonary arterial hypertension (PAH). Our
portfolio  of PAH treatments covers the spectrum of disease, from WHO Functional
Class  (FC) II through to FC IV, with oral, inhaled and intravenous medications.
Although  not available  in all  countries, Actelion  has treatments approved by
health  authorities for a number of specialist diseases including Type 1 Gaucher
disease,  Niemann-Pick type C disease, Digital Ulcers in patients suffering from
systemic  sclerosis,  and  mycosis  fungoides  in patients with cutaneous T-cell
lymphoma.

Founded  in late 1997, with now  over 2,600 dedicated professionals covering all
key  markets around the world including the US, Japan, China, Russia and Mexico,
Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion  shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN). All
trademarks are legally protected.

For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
www.actelion.com

 The  above information contains  certain "forward-looking statements", relating
to the company's business, which can be identified by the use of forward-looking
terminology  such as  "estimates",  "believes",  "expects", "may", "are expected
to",  "will",  "will  continue",  "should",  "would  be", "seeks",  "pending" or
"anticipates"  or similar expressions,  or by discussions  of strategy, plans or
intentions.   Such statements  include descriptions  of the company's investment
and research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and  anticipated customer demand for such products and products in the company's
existing  portfolio. Such  statements reflect  the current  views of the company
with  respect to future  events and are  subject to certain risks, uncertainties
and  assumptions. Many  factors could  cause the  actual results, performance or
achievements  of the company to be materially different from any future results,
performances  or achievements that may be  expressed or implied by such forward-
looking  statements.  Should  one  or  more  of  these  risks  or  uncertainties
materialize,  or should  underlying assumptions  prove incorrect, actual results
may  vary  materially  from  those  described  herein  as anticipated, believed,
estimated or expected.


Medienmitteilung PDF: 
http://hugin.info/131801/R/2104828/798821.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate
Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content,
accuracy and originality of the information contained therein.
    
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire

http://www.actelion.com